Pharmaceutical preparation
AssigneeBayer Aktiengesellschaft
InventorsJanne Olsen FRENVIK, Olav B. RYAN, Alan CUTHBERTSON
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for generating purified solution of at least on alpha-emitting radionuclide complex. The method comprises contacting a solution of the alpha-emitting radionuclide complex and at least one daughter nuclide with at least one selective binder for the daughter nuclide and subsequently separating the solution from the selective binder. The invention also provides a method for the removal of at least one daughter radionuclide from a solution comprising at least one alpha-emitting radionuclide complex. The method comprises contacting the solution with at least one selective binder for the daughter nuclide.
Claims34
A method for generating a purified solution of at least one alpha-emitting radionuclide, said method comprising contacting a solution comprising said least one alpha-emitting radionuclide complex and at least one daughter nuclide with at least one selective binder for said at least one daughter nuclide and subsequently separating said solution of at least one alpha-emitting radionuclide complex from said at least one selective binder.
A method for reducing the radiolysis of at least one organic component in a solution comprising at least one alpha-emitting radionuclide complex, at least one daughter radionuclide and at least one organic component, said method comprising contacting said solution with at least one selective binder for said at least one daughter nuclide.
A method for the removal of at least one daughter radionuclide from a solution comprising at least one alpha-emitting radionuclide complex, said method comprising contacting said solution with at least one selective binder for said at least one daughter nuclide.
A kit for the formation of a pharmaceutical preparation of at least one alpha-emitting radioisotope complex, said kit comprising:
- i) a solution of said at least one alpha-emitting radioisotope and at least one daughter isotope;
- ii) at least one ligand;
- ii) a specific binding moiety;
- iii) at least one selective binder for said at least one daughter isotope.
- wherein said alpha-emitting radioisotope is complexed or complexable by said ligand which is conjugated or conjugatable to said specific binding moiety.
An administration device comprising a solution of at least one alpha-emitting radionuclide complex and at least one daughter nuclide, said device further comprising a filter containing at least one selective binder for said daughter nuclide.
A method for the formation of an injectable solution of an alpha-radionuclide complex comprises the steps of:
- a) combining a first solution comprising a dissolved salt of an alpha-emitting radionuclide and at least one daughter nuclide with a second solution comprising at least one ligand conjugated to at least one targeting moiety;
- b) incubating the combined solutions at a suitable temperature (e.g. 0° C. to 50° C., preferably 20° C. to 40° C.) for a period to allow complex formation between said ligand and said alpha-emitting radioisotope whereby to form a solution of at least one alpha-emitting radioisotope complex;
- c) contacting said solution of at least one alpha-emitting radioisotope complex with at least one selective binder for at least one of said daughter nuclides.
- d) separating said solution of at least one alpha-emitting radionuclide complex from said at least one selective binder.
(canceled)
Dependencies are inferred from the claim text.